Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines

Oncogene

Volumn 26, Issue 10, 2007, Pages 1468-1476

  Kim, K E ^a   Song, H ^b   Kim, T S ^c   Yoon, D ^d   Kim, C W ^e   Bang, S I ^f   Hur, D Y ^b   Park, H ^g   Cho, D H ^a  

^a Sookmyung Women's University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Korea University   (South Korea)

^d Konkuk University   (South Korea)

^e Seoul National University   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

Author keywords

ERK1 2; F actin; IL 18; Migration; Tensin; VEGF

Indexed keywords

ACTIN; ANTIOXIDANT; ATENOLOL; INTERLEUKIN 18 BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MEDIATOR; METASTASIS; MOLECULAR DYNAMICS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR; UPREGULATION;

ACTINS; CELL MOVEMENT; HUMANS; INTERLEUKIN-18; MAP KINASE KINASE KINASES; MICROFILAMENT PROTEINS; RECOMBINANT PROTEINS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847350645     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209926     Document Type: Article

References (25)

1. Cao R, Farnebo J, Kurimoto M, Cao Y. (1999). Interleukin-18 acts as an angiogenensis andtumor suppressor. FASEB J 13: 2195-2202.
2. Carmeliet P, Jain RK. (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
3. Carrascal MT, Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N et al. (2003). Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 63: 491-497.
4. Chen J, De S, BrainardJ, Byzova TV. (2004). Metastatic properties of prostate cancer cells are controlledby VEGF. Cell Commun Adhes 11: 1-11.
5. Cho D, Kang JS, Park JH, Kim YI, Hahm E, Lee J et al. (2002). The enhanced IL-18 production by UVB irradiation requires ROI and AP-1 signaling in human keratinocyte cell line (HaCaT). Biochem Biophys Res Commun 298: 289-295.
6. Cho D, Song H, Kim YM, Houh D, Hur DY, Park H et al. (2000). Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligandand reactive oxygen intermediates. Cancer Res 60: 2703-2709.
7. Cumberbatch M, Dearman RJ, Antonopoulos C, Groves RW, Kimber I. (2001). Interleukin-18 induces Langerhans cell migration by a tumor necrosis factor-alpha- and IL-1 beta-dependent mechanism. Immunology 102: 323-330.
8. Gossart S, Cambon C, Orfila C, Seguelas MH, Lepert JC, Rami J et al. (1996). Reactive oxygen intermediates as regulators of TNF-alpha production in rat lung inflammation induced by silica. J Immunol 156: 1540-1548.
9. Horwitz AR, Parsons JT. (1999). Cell migration - movin' on. Science 286: 1102-1103.
10. Ishida Y, Migita K, Izumi Y, Nakao K, Ida H, Kawakami A et al. (2004). The role of IL-18 in the modulation of matrix metalloproteinases andmigration of human natural killer (NK) cells. FEBS Lett 569: 156-160.
11. Ju DW, Tao Q, Lou G, Bai M, He L, Yang Y et al. (2001). Interleukin-18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 61: 3735-3740.
12. Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M et al. (2000). Serum concentrations of interleukin-18 in early andad vancedcancer patients: enhanced-secretion in metastatic disease. J Biol Regul Homeost Agents 14: 275-277.
13. Lo SH. (2004). Tensin. Int J Biochem Cell Biol 36: 31-34.
14. Lo SH, Janmey PA, Hartwig JH, Chen LB. (1994). Interactions of tensin with actin andid entification of its three distinct actin-binding domain. J Cell Biol 125: 1067-1075.
15. Majima T, Ichikura T, Chochi K, Kawabata T, Tsujimoto H, Sugasawa H et al. (2006). Exploitation of interleukin-18 by gastric cancers for growth andevasion of host immunity. Int J Cancer 118: 388-395.
16. Meili R, Firtel RA. (2003). Two poles anda compass. Cell 114: 153-156.
17. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91.
18. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. (2001). Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167: 1644-1653.
19. Pedram A, Razandi M, Levin ER. (1998). Extracellular signalregulatedprotein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273: 26722-26728.
20. Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H et al. (1997). Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 159: 298-302.
21. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. (1995). Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, andproliferation of human colon cancer. Cancer Res 55: 3964-3968.
22. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H et al. (1997). Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor andnot via interferon-gamma to inhibit osteoclast formation. J Exp Med 185: 1005-1012.
23. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J et al. (2000). IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 97: 734-739.
24. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG et al. (2004). IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinase-9 (MMP-9) expression. Leukemia Res 28: 91-95.
25. Zhang H, Wu J, Meng L, Shou CC. (2002). Expression of vascular endothelial growth factor and its receptor KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8: 994-998.